Carlos Milla, M.D.

Interim Head, Assistant Professor
Director, Minnesota Cystic Fibrosis Center
Mayo Mail Code 742
420 Delaware Street
Minneapolis, MN  55455
Phone: (612) 626-2963 or 626-2916
Fax: (612) 624-0413
milla005@umn.edu

Dr Milla is an Assistant Professor in the division of Pulmonary & Critical Care. He is also the Director of the Minnesota CF Center, where he holds the Annalisa Marzotto Endowed Chair in Cystic Fibrosis Care.

After graduating from Medical School in Lima Peru, Dr Milla spent 2 years doing research work in Pediatric Nutrition. He then went on to complete Residency in Pediatrics at the Children's Medical Center of Brooklyn, State University of New York, Brooklyn, New York. Here he developed an interest in pulmonary diseases and clinical outcomes research. From New York he moved to Minneapolis where he completed sub-specialty training in Pediatric Pulmonology and Cystic Fibrosis at the University of Minnesota, as well as advanced training in Epidemiology and Biostatistics.

During his training Dr Milla became very interested in the care of CF patients and the monitoring of their outcomes, particularly their pulmonary function. His main area of research interest became the inflammatory responses that lead to airway disease and the metabolic factors that contribute to lung disease progression in CF. He has actively participated in multiple CF clinical research studies and has accumulated extensive experience on the study of longitudinal outcomes in CF. He has also been very active in Quality Improvement, identifying and implementing strategies to improve the clinical outcomes of patients with CF. This experience has been shared with other physicians and CF Centers across the country. This work has been possible through the Quality Improvement initiatives sponsored by the CF Foundation, with a goal of improving the care, and ultimately the outcomes, of all CF patients.

Selected Publications

Yang S, Milla CE, Panoskaltsis-Mortari A, Hawgood S, Blazar BR, Haddad IY. Surfactant Protein-A (SP-A) decreases lung injury and mortality after Murine Marrow Transplantation. Am J Respir Cell Mol Biol 2002; 27: 297-305.

Peterson M, Jacobs D, Milla CE. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. Pediatrics 2003;112:588-592.

Jackson A, Ternand C, Brunzell C, Kleinschmidt T, Dew D, Milla CE, Moran A. Insulin Glargine Improves Hemoglobin A1c in Children and Adolescents with Poorly Controlled Type 1 Diabetes. Pediatric Diabetes 2003; 4:64-49.

Olivier KN, Weber DJ, Wallace RJ, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, Edwards LJ, Chakraborti S, Knowles MR for the Nontuberculous Mycobacteria in Cystic Fibrosis Study Group, Milla CE and Warwick WJ, University of Minnesota. Non-tuberculous mycobacteria: I. Multicenter prevalence study in cystic fibrosis. Am J Resp Crit Care Med 2003; 167:828-834.

Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, Tomashefski J, Knowles MR for the Nontuberculous Mycobacteria in Cystic Fibrosis Study Group, Milla CE and Warwick WJ, University of Minnesota. Non-tuberculous mycobacteria: II. Nested cohort study of impact on cystic fibrosis lung disease. Am J Resp Crit Care Med 2003; 167:835-840.

Cornfield DN, Milla CE, Barbato JE, Park SJ. Inhaled Nitric Oxide decreases acute graft rejection in the first 28 days after transplantation. J Heart Lung Transpl 2003: 22:903-907.

Haddad IY, Milla CE, Yang S, Panoskaltsis-Mortari A, Hawgood S, Lacey DL, Blazar BR. Surfactant Protein A mediates the protective effects of Keratinocyte Growth Factor after experimental marrow transplantation. Am J Physiol: Lung Cell Mol Physiol 2003:L602-620.

Moran AM, Milla CE. Editorial. Abnormal glucose tolerance in cystic fibrosis: why should patients be screened. Pediatrics 2003; 142:97-99.

Milla CE, What is a Cystic Fibrosis pulmonary exacerbation? Pediatr Pulmonol 2003;S25:146-147.

Moss RB, Rodman D, Spencer LT, Aitken M, Zeitlin P, Waltz D, Milla CE, Brody A, Clancy JP, Ramsey B, Hamblett N, Heald AE. Repeated AAV2 Aerosol-mediated CFTR Gene Transfer to the Lungs of Patients with Cystic Fibrosis: A Multicenter, Double-Blind, Placebo-Controlled Trial. Chest 2004; 125:509-521.

Milla CE, Hansen LG, Warwick WJ. High frequency chest compression: Comparison of the second and third generation compression waveforms. Biomed Instrumentation technol 2004; 38:322-327.

Moran A. Basu R, Milla C, Jensen MD. Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance. Metabolism 2004; 11:1457-1472.

Garner HP, Perentesis JP, Boen JR, Phillips JR, Herron JG, Severson SJ, Kiffmeyer WR, Milla CE, Regelmann WE. Circulating Neutrophil Peroxidase Activity Correlates with Sputum Peroxidase Activity, Sputum Production and Airflow Obstruction in Cystic Fibrosis. J Lab Clin Invest 2004; 144:127-133.

Milla CE, Yang S, Cornfield DN, Brennan ML, Hazen S, Panoskaltsis-Mortari A, Blazar B, Haddad IY. Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol: Lung Cell Mol Physiol 2004; 287(4):L706-714 (Editorial comment in: Am J Physiol: Lung Cell Mol Physiol 287:L704-705).

Kotlikoff MI, Kannan Ms, Solway J, Deng KY, Deshpande DA, Dowell M, Feldman M, Green KS, JiG, Johnston R, Lakser O, Lee J, Lund FE, Milla C, Mitchell RW, Nakai J, Rishniw M, Walseth TF, White TA, Wilson J, Xin Hb, Woodruff PG. Methodological advancements in the study of airway smooth muscle. J Allergy Clin Immunol 2004; 114:S18-31.

Milla CE. Association of nutritional status and pulmonary function in children with Cystic Fibrosis (review). Current Opinion in Pulmonary Medicine 2004; 10:505-509.

Deshpande AD, White TA, Milla C, Walseth TF, Lund FE, Kannan MS. CD38 regulates intracellular calcium and responsiveness to agonists in airway smooth muscle. Am J Respir Cell Mol Biol 2005; 32:149-156.

Shukla M, Yang S, Milla C, Panoskaltsis-Mortari A, Blazar B, Haddad IY. The absence of host tumor necrosis factor receptor 1 attenuates the manifestations of idiopathic pneumonia syndrome. Am J Physiol: Lung Cell Mol Physiol 2005; 288:L942-L949.

Milla CE, Billings JL, Moran A. Diabetes is associated with dramatically decreased survival in women but not men with cystic fibrosis. (In press Diabetes Care).

Deterding RR, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin P, Milla CE, Marshall B, LaVange L, Engels J, Mathews D, Schaberg A, Williams J, Ramsey B, for the Cystic Fibrosis Foundation Therapeutics Development Network. Safety and Tolerability of Denufolsol Tetrasodium Inhalation Solution, a Novel P2Y2 Receptor Agonist: Results of a Phase 1/Phase 2 Multi-Center Study in Mild to Moderate Cystic Fibrosis. Pediatric Pulmonology 2005; 39:339-348.

Eikenberry M, Bartokova H, DeFor T, Haddad IY, Ramsay NKC, Blazar BR, Milla CE, Cornfield DN. Natural history of pulmonary complications in children following bone marrow transplantation. (BiolBlood Marrow Transpl 2005; 11(1):56-64.

Fekkol T, Rosenfeld M, Milla CE. Cystic Fibrosis pulmonary exacerbations. (In Review Journal of Pediatrics).